All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2020-04-22T14:12:59.000Z

Secondary acute myeloid leukemia: A risk factor for allogeneic stem cell transplantation in first complete remission

Apr 22, 2020
Share:

Bookmark this article

Secondary acute myeloid leukemia (sAML) evolves from underlying hematological conditions, such as myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN) and bone marrow failure disorders. sAML can also arise following subjection to radio- or chemotherapy, resulting in a unique subtype known as therapy related AML (tAML).1

Relative to de novo AML, the prognosis of sAML is poor, and patients respond inadequately to conventional chemotherapy and autologous stem cell transplants (auto-SCT). The front-line therapy for sAML is allogenic SCT (allo-SCT), however many patients lack human leukocyte antigen identical siblings.2

It remains unanswered whether sAML is, itself, a contributor to poor outcomes following allo-SCT. The Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT) aimed to address this question; conducting a retrospective comparison of patient outcomes following allo-SCT for the treatment of sAML vs de novo AML. Ann-Kristin Schmaelter and coinvestigators published the findings in Blood Cancer Journal and the AML Hub hereby presents a summary.2

Study design

  • Data from over 600 transplant centers were obtained from the EBMT registry for retrospective analysis
  • Adult patients receiving allo-SCT for the treatment of de novo (n = 11,439) or sAML (n = 1325) between January 2000 and December 2016 were eligible
  • Allo-SCT origin
    • matched related
    • 9/10 or 10/10 antigen matched unrelated
    • T-cell replete haploidentical donor
  • Primary outcomes: overall survival (OS), leukemia free survival (LFS), graft-versus-host disease (GvHD)/relapse free survival (GRFS), cumulative incidence of relapse (RI), non-relapse mortality (NRM), acute and chronic GvHD, and cause of death

Results

  • Median follow-ups after allo-SCT were 36.1 months and 33.1 months for patients with de novo AML and sAML respectively

Patient characteristics

  • Of the sAML cases, 62.5% arose from previous myeloid malignancy or bone marrow failure syndrome and 37.7% were tAML

Table 1. Baseline characteristics for patients receiving allo-SCT for the treatment of de novo AML and sAML

allo-SCT, allogenic stem cell transplantation; AML, acute myeloid leukemia; CR1/2, first/second complete remission; MAC, myeloablative conditioning; MSD, matched sibling donor; PIF, primary induction failure; RIC, reduced-intensity conditioning; sAML, secondary AML; SCT stem cell transplantation; UD, unrelated donor

*Allele compatibility for the human leukocyte antigen (HLA)

† Nine out of ten donor allele match to HLA

Characteristic, p < 0.001

De novo AML (n = 11,439)

sAML (n = 1325)

Median age at SCT, years (range)

49.3 (18–76.8)

57.7 (18.3–76)

Status at SCT, %

CR1

CR2

PIF

Relapse

 

67.23

18.64

5.31

8.82

 

68.6

7.02

15.02

9.36

Donor

MSD

UD 10/10*

UD 9/10†

Haploidentical donor

 

55.99

28.68

9.05

6.28

 

43.62

39.09

10.49

6.79

Cytogenetics

Favorable

Intermediate

Adverse

 

13.04

68.27

18.69

 

4.38

63.09

32.53

Graft source

Bone marrow

Peripheral blood

 

17.53

82.47

 

12.23

87.77

Conditioning regimen

MAC

RIC

 

55.13

43.32

 

44.87

56.68

Patient outcomes

  • The majority of patients reached engraftment following allo-SCT irrespective of diagnosis (Table 2)
  • The most common cause of death was recurrence of original disease

Table 2. Patient outcomes to allo-SCT by diagnosis

allo-SCT, allogenic stem cell transplantation; AML, acute myeloid leukemia; aGvHD, acute graft-versus-host disease; cGvHD, chronic GvHD; GRFS, GvHD/relapse-free survival; LFS, leukemia free survival; OS, overall survival; RI, incidence of relapse; sAML, secondary AML; SCT stem cell transplantation

Outcome, %

De novo AML (n = 11,439)

sAML (n = 1325)

Engraftment

98.2

96.6

Patient outcome at 3 years

OS

LFS

NRM

RI

GRFS

 

54.6

48.9

18

33

34.3

 

43.1

37.9

24.8

37.3

25.8

Grade 34 GvHD

aGvHD

cGvHD

 

23.5

40.6

 

24.4

35.4

Transplantation in complete remission 1 (CR1)

  • As there was a significant interaction between diagnosis (de novo vs sAML) and disease status at the time of allo-SCT (Table 1), the impact of sAML was stratified by patient disease status at the time of allo-SCT
    • Most patients received SCT during CR1 ( Table 1)
    • A univariate analysis was conducted comparing the outcomes of patients transplanted in this period (Table 3)
    • sAML diagnosis had a negative impact on the 3-year patient outcomes (Table 3)

Table 3. The 3-year outcomes of patients receiving allo-SCT during CR1

AML, acute myeloid leukemia; CR1, first complete remission; GRFS, graft-versus-host disease (GvHD)/relapse-free survival; LFS, leukemia free survival; OS, overall survival; sAML, secondary AML

Outcome, %

De novo AML (n = 11,439)

sAML (n = 1325)

p

OS

60.8

46.7

< 0.00001

Relapse

28.5

35

0.000086

NRM

16.4

23.4

< 0.00001

LFS

55.1

41.6

< 0.00001

GRFS

38.6

28.4

< 0.00001

 

  • A multivariate analysis of patients receiving allo-SCT during CR1 also concluded that sAML was associated with significantly reduced OS, LFS, GRFS and increased cumulative NRM and RI (Table 4)
    • This did not translate to patients receiving transplants during primary induction failure (PIF) or active relapse
  • sAML was not a significant risk factor for GvHD progression
  • A matched-pair analysis (n = 877 pairs) supplemented the findings; reinforcing that sAML significantly worsens patient outcomes to allo-SCT when compared to de novo AML

Table 4. Multivariate analysis of patients receiving allo-SCT during CR1

CI, confidence interval; GRFS, graft-versus-host disease (GvHD)/relapse-free survival; HR, hazard ratio; LFS, leukemia free survival; NRM, non-relapse mortality; OS, overall survival; RI, incidence

Outcome

HR

95% CI

p

OS

1.33

1.21–1.48

< 0.00001

LFS

1.32

1.19–1.45

< 0.00001

GRFS

1.20

1.10–1.31

< 0.0001

NRM

1.37

1.17–1.59

< 0.001

RI

1.27

1.12–1.44

< 0.0001

 Conclusion

  • sAML, including tAML, was identified as an independent risk factor for OS, LFS, GRFS, RI, and NRM after allo-SCT during CR1
  • Long-term remission of sAML is poor, irrespective of previous treatment and induction therapies
  • The data from this study could be applied to improve transplant protocols, risk stratifications and prognostic valuations in patients receiving allo-HCT for sAML
  • Limitations:
    • Where cytogenetic information was unavailable, patients were excluded from the analysis which introduced a selection bias
    • There was a significant lack of information on MRD status and pre- and post-transplant therapies in most patients
    • Patients receiving allo-SCT in the second remission were likely underrepresented in the matched-pair analysis

  1. Boddu P et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017 Jul 19; 1(17):1312– DOI: 10.1182/bloodadvances.2017008227
  2. Schmaelter AK et al. Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia. Blood Cancer J. 2020 Mar 3; 10(3):26. DOI: 1038/s41408-020-0296-3

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
15 votes - 79 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox